伊布替尼

伊布替尼
臨床資料
商品名（英語：Drug nomenclature）	Imbruvica, others
其他名稱	PCI-32765, CRA-032765
AHFS/Drugs.com	Monograph
MedlinePlus	a614007
核准狀況	美 DailyMed: Ibrutinib;
懷孕分級	澳: D ; ;
給藥途徑	口服給藥
ATC碼	L01EL01 (WHO) ;
法律規範狀態
法律規範	澳：限醫生處方（S4）; 加：處方藥（℞-only）; 歐：Rx-only; 英：處方藥（℞-only） (POM); 美：處方藥（℞-only）; 處方藥（℞-only）;
藥物動力學數據
血漿蛋白結合率	97.3%
藥物代謝	肝 (CYP3A（英語：CYP3A） & CYP2D6)
生物半衰期	4–6 小時
排泄途徑	糞便 (80%), 尿液 (10%)
識別資訊
	IUPAC命名法 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; ;
CAS號	936563-96-1
PubChem CID	24821094;
IUPHAR/BPS	6912;
DrugBank	DB09053;
ChemSpider	26637187;
UNII	1X70OSD4VX;
KEGG	D10223;
ChEBI	CHEBI:76612;
ChEMBL	ChEMBL1873475;
PDB配體ID	1E8 (PDBe, RCSB PDB);
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID60893450 ;
ECHA InfoCard	100.232.543
化學資訊
化學式	C25H24N6O2
摩爾質量	440.51 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N;
	InChI InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1; Key:XYFPWWZEPKGCCK-GOSISDBHBU;

伊布替尼（Ibrutinib）用於治療被套細胞淋巴瘤（mantle cell lymphoma，MCL）、慢性淋巴細胞白血病（chronic lymphocytic leukemia，CLL）和華氏巨球蛋白血症（英語：Waldenström macroglobulinemia）（Waldenström's macroglobulinemia）的口服藥物^[8] ^[9]。當以上淋巴瘤和白血病以用於其他治療無效時，可考慮使用^[9]。也可能用於移植物抗宿主病^[8]。

常見副作用包括血小板減少症、貧血、白細胞減少症、腹瀉、皮疹、出血和口腔發炎^[8]。其他副作用包括可能感染、心臟衰竭、高血壓、其他癌症和腫瘤溶解症候群（英語：Tumor lysis syndrome）^[8]。孕期使用可能對胎兒有害^[8]。作用機轉是阻斷布魯頓酪氨酸激酶（英語：Bruton's tyrosine kinase）（Bruton's tyrosine kinase，BTK），進而減緩B細胞的分裂與數量^[9]。

伊布替尼分別於 2013 年與2014年在美國與歐洲取得醫療使用許可^[10] ^[9]。名世界衛生組織基本藥物標準清單^[11]。已有學名藥流通於市^[12]。

參考文獻

^ Ibrutinib (Imbruvica) Use During Pregnancy. Drugs.com. 3 December 2019 [28 March 2020].
^ Prescription medicines: registration of new chemical entities in Australia, 2015. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023].
^ Regulatory Decision Summary for Imbruvica. Drug and Health Products Portal. 4 August 2023 [2 April 2024].
^ Imbruvica 140 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC). (emc). 16 January 2020 [28 March 2020].
^ UK Ibrutinib label. UK Electronic Medicines Compendium. 25 August 2016 [20 November 2016]. （原始內容存檔於30 July 2019）.
^ Imbruvica- ibrutinib capsule Imbruvica- ibrutinib tablet, film coated. DailyMed. 8 April 2020 [21 April 2020].
^ Imbruvica EPAR. European Medicines Agency (EMA). 8 July 2021 [14 July 2021].
^ ^8.0 ^8.1 ^8.2 ^8.3 ^8.4 Imbruvica- ibrutinib capsule Imbruvica- ibrutinib tablet, film coated. DailyMed. 8 April 2020 [21 April 2020]. （原始內容存檔於12 August 2020）.
^ ^9.0 ^9.1 ^9.2 ^9.3 Imbruvica EPAR. European Medicines Agency (EMA). 8 July 2021 [14 July 2021]. （原始內容存檔於10 April 2021）.
^ Ibrutinib Monograph for Professionals. Drugs.com. [24 November 2021]. （原始內容存檔於10 July 2020）（英語）.
^ World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. WHO/MHP/HPS/EML/2021.02.
^ Ibrutinib: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [19 June 2021]. （原始內容存檔於24 June 2021）.

[Drugs.com_pregnancy-1] Ibrutinib (Imbruvica) Use During Pregnancy. Drugs.com. 3 December 2019 [28 March 2020].

[2] Prescription medicines: registration of new chemical entities in Australia, 2015. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023].

[3] Regulatory Decision Summary for Imbruvica. Drug and Health Products Portal. 4 August 2023 [2 April 2024].

[4] Imbruvica 140 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC). (emc). 16 January 2020 [28 March 2020].

[UKlabel2016-5] UK Ibrutinib label. UK Electronic Medicines Compendium. 25 August 2016 [20 November 2016]. （原始內容存檔於30 July 2019）.

[Imbruvica_FDA_label-6] Imbruvica- ibrutinib capsule Imbruvica- ibrutinib tablet, film coated. DailyMed. 8 April 2020 [21 April 2020].

[Imbruvica_EPAR-7] Imbruvica EPAR. European Medicines Agency (EMA). 8 July 2021 [14 July 2021].

[PI2021-8] 8.0 ^8.1 ^8.2 ^8.3 ^8.4 Imbruvica- ibrutinib capsule Imbruvica- ibrutinib tablet, film coated. DailyMed. 8 April 2020 [21 April 2020]. （原始內容存檔於12 August 2020）.

[EPAR2021-9] 9.0 ^9.1 ^9.2 ^9.3 Imbruvica EPAR. European Medicines Agency (EMA). 8 July 2021 [14 July 2021]. （原始內容存檔於10 April 2021）.

[10] Ibrutinib Monograph for Professionals. Drugs.com. [24 November 2021]. （原始內容存檔於10 July 2020）（英語）.

[WHO22nd-11] World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. WHO/MHP/HPS/EML/2021.02.

[12] Ibrutinib: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [19 June 2021]. （原始內容存檔於24 June 2021）.

[8]

[9]

[1]

[2]

[3]

[7]

[4]

[5]

[6]

[10]

[11]

[12]